Abstract:CD4 mimics are small molecules that inhibit the interaction of gp120 with CD4. We have developed several CD4 mimics. Herein, hybrid molecules consisting of CD4 mimics with a long alkyl chain or a PEG unit attached through a self-cleavable linker were synthesized. In anti-HIV activity, modification with a PEG unit appeared to be more suitable than modification with a long alkyl chain. Thus, hybrid molecules of CD4 mimics, with PEG units attached through an uncleavable linker, were developed and showed high anti-HIV activity and low cytotoxicity. In investigation of pharmacokinetics in a rhesus macaque, a hybrid compound had a more effective PK profile than that of the parent compound, and intramuscular injection was a more useful administration route to maintain the high blood concentration of the CD4 mimic than intravenous injection. The presented hybrid molecules of CD4 mimics with a PEG unit would be practically useful when combined with a neutralizing antibody.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01153?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01153</a>.Experimental procedures of compound synthesis including characterization data, a calibration curve of YIR-821·2TFA used to calculate PK in a rhesus macaque, degradation experiments of the hybrid molecule 45 in the PBS solution (pH 7.4) at 37 °C, a calibration curve of the hybrid molecule 58·2TFA used to calculate PK in a rhesus macaque by iv injection, a calibration curve of 58·2TFA used to calculate PK in a rhesus macaque by im injection, the structures of YIR-821 and compound 58 docked in gp120, HPLC analysis of evaluation of the biological stability of compound 58·2TFA treated with human liver microsomes, FACS analysis of EGFP and HIV-1 JR-FL envelope (Env) expressing HEK293T cells treated with anti-CD4i antibodies, and inhibition of gp120-CD4 binding by compound 58 and YIR-821 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_001.pdf">PDF</a>)Molecular formula strings of 2–22, 24, 30, 32, 35, 36, 38–46, 49, 50, 54, 58, and 62 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01153/suppl_file/jm0c01153_si_002.csv">CSV</a>)This article has not yet been cited by other publications.

Soluble-type small-molecule CD4 mimics as HIV entry inhibitors

Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors

Small-Molecule CD4 Mimics Containing Mono-cyclohexyl Moieties as HIV Entry Inhibitors

A minimally cytotoxic CD4 mimic as an HIV entry inhibitor

Flexibility of small molecular CD4 mimics as HIV entry inhibitors

Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors

In Silico Identification of Novel Aromatic Compounds As Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4

Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors

Identification of N-phenyl-N′-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4

Characterization of a Novel CD4 Mimetic Compound YIR-821 against HIV-1 Clinical Isolates

N-Phenyl-N'-(2,2,6,6-Tetramethyl-Piperidin-4-Yl)-Oxalamides As A New Class Of Hiv-1 Entry Inhibitors That Prevent Gp120 Binding To Cd4

In Silico Identification of High-Affinity Ligands of the Hiv-1 Gp120 Protein, Potential Peptidomimetics of Neutralizing Antibody N6

Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins

Design, Synthesis, and Biological Activity of Novel 1,4-Disubstituted Piperidine/piperazine Derivatives As CCR5 Antagonist-Based HIV-1 Entry Inhibitors

IDENTIFICATION OF FUNCTIONAL MIMETICS OF ANTI-HIV ANTIBODY N6 BY METHODS OF VIRTUAL SCREENING AND MOLECULAR MODELING

Exceptionally Potent and Broadly Cross-Reactive, Bispecific Multivalent Hiv-1 Inhibitors Based on Single Human Cd4 and Antibody Domains

A “Two-Birds-One-Stone” Approach toward the Design of Bifunctional Human Immunodeficiency Virus Type 1 Entry Inhibitors Targeting the CCR5 Coreceptor and gp41 N-Terminal Heptad Repeat Region

Structural Mimicry of CD4 by a Cross-reactive HIV-1 Neutralizing Antibody with CDR-H2 and H3 Containing Unique Motifs

Targeting dual tolerant regions of binding pocket: Discovery of novel morpholine-substituted diarylpyrimidines as potent HIV-1 NNRTIs with significantly improved water solubility

A Novel CXCR4 Targeting Protein SDF-1/54 As an HIV-1 Entry Inhibitor.

N-Substituted Pyrrole Derivative 12m Inhibits HIV-1 Entry by Targeting Gp41 of HIV-1 Envelope Glycoprotein